Petiq, Inc. (PETQ)

$20.62

-0.14

(-0.67%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Petiq, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 219.92M → 308.44M (in $), with an average increase of 28.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -17.48M → 14.90M (in $), with an average increase of 217.3% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 51.6% return, outperforming this stock by 0.2%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 48.2% return, outperforming this stock by 94.6%

Performance

  • $20.55
    $20.96
    $20.62
    downward going graph

    0.36%

    Downside

    Day's Volatility :1.98%

    Upside

    1.62%

    downward going graph
  • $13.04
    $22.98
    $20.62
    downward going graph

    36.76%

    Downside

    52 Weeks Volatility :43.26%

    Upside

    10.27%

    downward going graph

Returns

PeriodPetiq, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
22.88%
-1.0%
0.0%
6 Months
14.43%
9.6%
0.0%
1 Year
56.57%
11.0%
0.0%
3 Years
-46.37%
18.5%
-22.6%

Highlights

Market Capitalization
616.2M
Book Value
$8.01
Earnings Per Share (EPS)
0.23
PE Ratio
90.04
PEG Ratio
1.56
Wall Street Target Price
29.0
Profit Margin
0.65%
Operating Margin TTM
7.99%
Return On Assets TTM
4.28%
Return On Equity TTM
3.38%
Revenue TTM
1.1B
Revenue Per Share TTM
38.39
Quarterly Revenue Growth YOY
6.2%
Gross Profit TTM
209.7M
EBITDA
95.9M
Diluted Eps TTM
0.23
Quarterly Earnings Growth YOY
0.48
EPS Estimate Current Year
1.46
EPS Estimate Next Year
1.7
EPS Estimate Current Quarter
0.43
EPS Estimate Next Quarter
0.52

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Petiq, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 40.64%

Current $20.62
Target $29.00

Company Financials

FY18Y/Y Change
Revenue
528.6M
↑ 98.22%
Net Income
-782.0K
↓ 77.61%
Net Profit Margin
-0.15%
↑ 1.16%
FY19Y/Y Change
Revenue
709.4M
↑ 34.21%
Net Income
-14.3M
↑ 1728.9%
Net Profit Margin
-2.02%
↓ 1.87%
FY20Y/Y Change
Revenue
780.1M
↑ 9.95%
Net Income
-81.0M
↑ 466.51%
Net Profit Margin
-10.39%
↓ 8.37%
FY21Y/Y Change
Revenue
932.5M
↑ 19.55%
Net Income
-16.4M
↓ 79.78%
Net Profit Margin
-1.76%
↑ 8.63%
FY22Y/Y Change
Revenue
921.5M
↓ 1.18%
Net Income
-48.6M
↑ 196.77%
Net Profit Margin
-5.28%
↓ 3.52%
FY23Y/Y Change
Revenue
1.1B
↑ 19.58%
Net Income
2.1M
↓ 104.38%
Net Profit Margin
0.19%
↑ 5.47%
Q4 FY22Q/Q Change
Revenue
184.1M
↓ 12.23%
Net Income
-6.9M
↓ 86.1%
Net Profit Margin
-3.74%
↑ 19.9%
Q1 FY23Q/Q Change
Revenue
290.5M
↑ 57.8%
Net Income
9.7M
↓ 240.81%
Net Profit Margin
3.34%
↑ 7.08%
Q2 FY23Q/Q Change
Revenue
314.5M
↑ 8.29%
Net Income
9.5M
↓ 2.38%
Net Profit Margin
3.01%
↓ 0.33%
Q3 FY23Q/Q Change
Revenue
277.0M
↓ 11.93%
Net Income
451.0K
↓ 95.24%
Net Profit Margin
0.16%
↓ 2.85%
Q4 FY23Q/Q Change
Revenue
219.9M
↓ 20.61%
Net Income
-17.5M
↓ 3977.38%
Net Profit Margin
-7.95%
↓ 8.11%
Q1 FY24Q/Q Change
Revenue
308.4M
↑ 40.25%
Net Income
14.9M
↓ 185.25%
Net Profit Margin
4.83%
↑ 12.78%
FY18Y/Y Change
Total Assets
495.4M
↑ 251.76%
Total Liabilities
174.5M
↑ 384.59%
FY19Y/Y Change
Total Assets
672.7M
↑ 35.79%
Total Liabilities
344.4M
↑ 97.42%
FY20Y/Y Change
Total Assets
771.6M
↑ 14.7%
Total Liabilities
477.6M
↑ 38.66%
FY21Y/Y Change
Total Assets
819.6M
↑ 6.22%
Total Liabilities
564.4M
↑ 18.17%
FY22Y/Y Change
Total Assets
818.9M
↓ 0.08%
Total Liabilities
607.1M
↑ 7.57%
FY23Y/Y Change
Total Assets
868.2M
↑ 6.02%
Total Liabilities
645.2M
↑ 6.28%
Q4 FY22Q/Q Change
Total Assets
818.9M
↑ 103333.31%
Total Liabilities
607.1M
↑ 105226.32%
Q1 FY23Q/Q Change
Total Assets
867.7M
↑ 5.96%
Total Liabilities
644.6M
↑ 6.17%
Q2 FY23Q/Q Change
Total Assets
883.5M
↑ 1.82%
Total Liabilities
647.9M
↑ 0.51%
Q3 FY23Q/Q Change
Total Assets
857.1M
↓ 2.99%
Total Liabilities
617.9M
↓ 4.62%
Q4 FY23Q/Q Change
Total Assets
868.2M
↑ 1.3%
Total Liabilities
645.2M
↑ 4.42%
Q1 FY24Q/Q Change
Total Assets
875.2M
↑ 0.81%
Total Liabilities
637.4M
↓ 1.22%
FY18Y/Y Change
Operating Cash Flow
-12.4M
↓ 311.03%
Investing Cash Flow
-100.0M
↑ 2320.75%
Financing Cash Flow
141.0M
↑ 298.55%
FY19Y/Y Change
Operating Cash Flow
20.8M
↓ 267.83%
Investing Cash Flow
-195.0M
↑ 95.02%
Financing Cash Flow
135.1M
↓ 4.19%
FY20Y/Y Change
Operating Cash Flow
-4.6M
↓ 122.09%
Investing Cash Flow
-118.0M
↓ 39.48%
Financing Cash Flow
128.8M
↓ 4.66%
FY21Y/Y Change
Operating Cash Flow
23.8M
↓ 616.56%
Investing Cash Flow
-26.1M
↓ 77.85%
Financing Cash Flow
48.3M
↓ 62.46%
FY22Y/Y Change
Operating Cash Flow
48.0M
↑ 102.06%
Investing Cash Flow
-12.0M
↓ 54.19%
Financing Cash Flow
-13.7M
↓ 128.37%
Q4 FY22Q/Q Change
Operating Cash Flow
48.9M
↓ 24.21%
Investing Cash Flow
-2.2M
↑ 22.87%
Financing Cash Flow
-2.3M
↓ 79.21%
Q1 FY23Q/Q Change
Operating Cash Flow
-43.3M
↓ 188.61%
Investing Cash Flow
-29.5M
↑ 1257.72%
Financing Cash Flow
-3.1M
↑ 33.65%
Q2 FY23Q/Q Change
Operating Cash Flow
57.7M
↓ 233.24%
Investing Cash Flow
-2.2M
↓ 92.49%
Financing Cash Flow
-2.5M
↓ 19.51%

Technicals Summary

Sell

Neutral

Buy

Petiq, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Petiq, Inc.
Petiq, Inc.
16.83%
14.43%
56.57%
-46.37%
-25.83%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-1.26%
20.07%
49.07%
48.24%
66.16%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
2.79%
0.0%
2.67%
14.3%
14.3%
Zoetis Inc.
Zoetis Inc.
3.87%
-5.35%
0.73%
-1.62%
59.42%
Viatris Inc.
Viatris Inc.
-10.49%
9.3%
13.4%
-31.25%
-35.25%
Catalent, Inc.
Catalent, Inc.
-3.71%
35.8%
43.6%
-46.34%
16.03%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Petiq, Inc.
Petiq, Inc.
90.04
90.04
1.56
1.46
0.03
0.04
NA
8.01
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
36.8
36.8
0.44
4.07
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.13
28.13
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
32.67
32.67
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.25
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Petiq, Inc.
Petiq, Inc.
Buy
$616.2M
-25.83%
90.04
0.65%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.6B
66.16%
36.8
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.5B
14.3%
28.13
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$77.4B
59.42%
32.67
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.6B
-35.25%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$9.7B
16.03%
211.02
-28.44%

Institutional Holdings

  • BlackRock Inc

    9.92%

  • Vanguard Group Inc

    7.63%

  • Eos Management LP

    6.68%

  • Aristotle Capital Boston, LLC

    4.42%

  • Dimensional Fund Advisors, Inc.

    4.04%

  • Boston Partners Global Investors, Inc

    3.62%

Company Information

petiq is founded with a love of pets and a desire to improve pet lives with veterinarian recommended pet products, made here in the usa. petiq offers pet prescription medications, over-the-counter flea & tick preventatives, health & wellness supplements, and dog & cat treats - at savings to other brand name alternatives. the company's portfolio of brands includes minties® dental treats, advecta® and petaction® flea and tick preventatives, vetiq® health & wellness, delightibles® cat treats, and betsy farms® dog treats. products are distributed nationally through traditional retail partners. petiq is headquartered in eagle, idaho with manufacturing and distribution facilities in springville, utah; plano, texas; and daytona beach, florida. to learn more, visit petiq.com.

Organization
Petiq, Inc.
Employees
1121
CEO
Mr. McCord Christensen
Industry
Health Technology

Discover More

FAQs